Can biosimilars help achieve the goals of US health care reform?

References

• US CongressThe Patient Protection and Affordable Care ActWashington, DCUS Department of Health & Human Services, Healthcare.gov2010 [updated March 23, 2010]. Available from: https://www.healthcare.gov/glossary/patient-protection-and-affordable-care-act/Accessed April 6, 2017
   Google Scholar
• ObamaBUnited States health care reform: progress to date and next stepsJAMA2016316552553227400401
   PubMed Web of Science ®Google Scholar
• OrszagPRUS health care reform: cost containment and improvement in qualityJAMA2016316549349527400156
   PubMed Web of Science ®Google Scholar
• US CongressKey features of the Affordable Care Act by yearBaltimore, MDUS Department of Health & Human Services2015 [updated November 18, 2014]. Available from: http://www.hhs.gov/healthcare/facts-and-features/key-features-of-aca/Accessed April 6, 2017
   Google Scholar
• US CongressThe Patient Protection and Affordable Care Act Biologics Price Competition and Innovation ActWashington, DCResponsible Reform for the Middle Class2009 Available from: https://www.dpc.senate.gov/healthreformbill/healthbill27.pdfAccessed April 6, 2017
   Google Scholar
• US Food and Drug AdministrationLabeling for biosimilar products Guidance for industry: Draft guidanceSilver Spring, MDUS Department of Health & Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)2016 [updated March 2016]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM493439.pdfAccessed April 6, 2017
   Google Scholar
• Center for Drug Evaluation and ResearchList of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to dateSilver Spring, MDUS Food and Drug Administration2016 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM439049.pdfAccessed April 6, 2017
   Google Scholar
• European Medicines AgencyEuropean public assessment reportsLondonEuropean Medicines Agency2016 [updated October 6, 2016]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=SubmitAccessed April 6, 2017
   Google Scholar
• FalitBPSinghSCBrennanTABiosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managersHealth Aff (Millwood)201534229430125646110
   PubMed Web of Science ®Google Scholar
• BrougherJTThe Biosimilars Act: promoting or discouraging the development of generic biologics?: a tug-of-war between generic and innovator biologics seems to be where drug developers are headedBiotechnol Healthc2010742223
   Google Scholar
• US Food and Drug AdministrationNonproprietary naming of biologic products Guidance for industrySilver Spring, MDUS Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)2017 [updated January 2017]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm459987.pdfAccessed April 6, 2017
   Google Scholar
• IMS Institute for Healthcare InformaticsDelivering on the potential of biosimilar medicines. The role of functioning competitive marketsParsippany, NJIMS Health2016 Available from: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdfAccessed April 6, 2017
   Google Scholar
• BauchnerHThe Affordable Care Act and the future of US health careJAMA2016316549249327399990
   PubMed Web of Science ®Google Scholar
• SkinnerJChandraAThe past and future of the Affordable Care ActJAMA2016316549749927400390
   PubMed Web of Science ®Google Scholar
• YeungWBurnsH3rd, Loiacono D. Are ACOs the answer to high-value healthcare?Am Health Drug Benefits20114744145025126368
   PubMedGoogle Scholar
• ButlerSMThe future of the Affordable Care Act. Reassessment and revisionJAMA2016316549549727400269
   PubMed Web of Science ®Google Scholar
• EvansMDartmouth-Hitchcock exits Medicare’s Pioneer ACO programNew York, NYModern Healthcare2015 [updated October 20, 2015]. Available from: http://www.modernhealthcare.com/article/20151020/NEWS/151029984Accessed April 6, 2017
   Google Scholar
• TracerZUnitedHealth to exit Obamacare in 16 states to stem lossesNew York, NYBloomberg2016 [updated April 16, 2016]. Available from: http://www.bloomberg.com/news/articles/2016-04-19/united-health-profit-beats-estimates-fueled-by-tech-unit-optumAccessed April 6, 2017
   Google Scholar
• BlackstoneEAJosephPFThe economics of biosimilarsAm Health Drug Benefits20136846947824991376
   PubMedGoogle Scholar
• IMS Institute for Healthcare InformaticsShaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscapeParsippany, NJIMS Health2011 Available from: http://weinberg-group.com/pdfs/Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_biosimiliars_landscape.pdfAccessed April 6, 2017
   Google Scholar
• Centers for Medicare & Medicaid ServicesMemorandum: Part D requirements for biosimilar follow-on biological productsBaltimore, MDUS Department of Health & Human Services2015 [updated March 30, 2015]. Available from: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=19358Accessed April 6, 2017
   Google Scholar
• MulcahyAWPredmoreZMattkeSThe cost savings potential of biosimilar drugs in the United StatesSanta Monica, CARand Corporation2014 Available from: https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdfAccessed April 6, 2017
   Google Scholar
• KitamuraMBullied in Norway, Merck sees sales of blockbuster diveNew York, NYBloomberg2015 [updated April 22, 2015]. Available from: http://www.bloomberg.com/news/articles/2015-04-22/merck-gets-bullied-in-norway-with-remicade-price-warAccessed April 6, 2017
   Google Scholar
• StantonDBiosimilar discounts and switching will wipe-out J&J’s Remicade in Norway, says regulator [news report]Crawley, EnglandBioPharma-Reporter.com, William Reed Business Media2015 [updated October 16, 2015]. Available from: http://www.biopharma-reporter.com/Markets-Regulations/Biosimilar-discounts-will-wipe-out-Janssen-s-Remicade-sales-in-NorwayAccessed April 6, 2017
   Google Scholar
• DornerTStrandVCornesPThe changing landscape of biosimilars in rheumatologyAnn Rheum Dis201675697498226964144
   PubMed Web of Science ®Google Scholar
• Farfan-PortetMIGerkensSLepage-NefkensIVinckIHulstaertFAre biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?Eur J Health Econ201415322322824271016
   PubMed Web of Science ®Google Scholar
• DrummondMMartinMBiosimilar value generation or value destruction? A workshop demonstrating uptake to date and quantifying savings made19th Annual European Congress of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR)November 2, 2016Vienna, Austria
   Google Scholar
• WhitfieldEAdlerJGebremariamADavisMInsurance among young adults with inflammatory bowel disease: changes under the Affordable Care Act Dependent ProvisionJ Pediatr Gastroenterol Nutr Epub2016810
   Web of Science ®Google Scholar
• TrottaFMayerFMecozziAAmatoLAddisAImpact of guidance on the prescription patterns of G-CSFs for the prevention of febrile neutropenia following anticancer chemotherapy: a population-based utilization study in the Lazio RegionBioDrugs201731211712428353170
   PubMed Web of Science ®Google Scholar
• SunDAndayaniTMAltyarAMacDonaldKAbrahamIPotential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation studyClin Ther201537484285725704107
   PubMed Web of Science ®Google Scholar
• CVS Health2017 formulary management strategy and 2017 standard formulary list of removals and updatesWoonsocket, RICVS Caremark2016 [updated 2016]. Available from: http://investors.cvshealth.com/~/media/Files/C/CVS-IR-v3/documents/02-aug-2016/2017-standard-formulary-list-of-removals-and-updates.pdfAccessed April 6, 2017
   Google Scholar
• Bonakdar TehraniACunninghamPJClosing the Medicare doughnut hole: changes in prescription drug utilization and out-of-pocket spending among Medicare beneficiaries with Part D coverage after the Affordable Care ActMed Care2017551434927547949
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services2017 ASP drug pricing files April 2017 updateBaltimore, MDUS Department of Health & Human Services, cms.gov;2017 [updated March 20, 2017]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.htmlAccessed April 6, 2017
   Google Scholar
• Centers for Medicare & Medicaid ServicesQuestions and answers about biosimilar productsBaltimore, MDMLN Matters2015 Available from: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE1509.pdfAccessed April 6, 2017
   Google Scholar
• BalanescuAWilandPMaximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservationRheumatol Int20133361379138623300003
   PubMed Web of Science ®Google Scholar
• KennedyJWoodEGMedication costs and adherence of treatment before and after the Affordable Care Act: 1999–2015Am J Public Health2016106101804180727552279
   PubMed Web of Science ®Google Scholar
• LiangBAMackeyTEmerging patient safety issues under health care reform: follow-on biologics and immunogenicityTher Clin Risk Manag2011748949322241945
   PubMed Web of Science ®Google Scholar
• DummitLAKahveciogluDMarrufoGAssociation between hospital participation in a Medicare bundled payment initiative and payments and quality outcomes for lower extremity joint replacement episodesJAMA2016316121267127827653006
   PubMed Web of Science ®Google Scholar
• DalzellMDHow will biologics fit into healthcare reform? With so many variables, it’s hard to predict what kind of market will exist for biologics and other specialty drugs in 2014. Current trends may provide some insightBiotechnol Healthc20118461022479228
   PubMedGoogle Scholar
• OlsonKASBM labeling surveyCary, NCIndustry Standard Research (ISR)2015 [updated February 2015]. Available from: http://docs.house.gov/meetings/IF/IF14/20160204/104408/HHRG-114-IF14-20160204-SD010.pdfAccessed April 6, 2017
   Google Scholar
• BiosimilarsCME.orgExploring the future of biological therapy and the role of biosimilars. White PaperOld Lyme, CTThe France Foundation2015 [updated June 30, 2015]. Available from: http://www.biosimilarscme.org/content/Biosimilars_whitepaper.pdfAccessed April 6, 2017
   Google Scholar
• Coalition of State Rheumatology Organizations (CSRO)CSRO releases Physician Biosimilars Survey results [press release]Schaumburg, ILCSRO2016 [updated May 26, 2016]. Available from: http://csro.info/app/document/8382846;jsessionid=P5zJOo6TwPYoXVXzwSYawvyM.undefinedAccessed April 6, 2017
   Google Scholar
• Alliance for Safe Biologic Medicines (ASBM)New ASBM survey provides physicians’ views on biosimilar labeling [news release]Arlington, VASafeBiologics2015 Available from: https://safebiologics.org/2015/03/new-asbm-survey-provides-physicians-views-on-biosimilar-labeling/Accessed April 6, 2017
   Google Scholar
• HallerstenAFurstWMezzasalmaRPhysicians prefer greater detail in the biosimilar label (SmPC). Results of a survey across seven European countriesRegul Toxicol Pharmacol20167727528127041395
   PubMed Web of Science ®Google Scholar
• CohenHBeydounDChienDAwareness, knowledge, and perceptions of biosimilars among specialty physiciansAdv Ther201633122160217227798772
   PubMed Web of Science ®Google Scholar
• JainRHSchleicherSMAtoriaCLBachPBPart B payment for drugs in Medicare: Phase 1 of CMS’ proposed pilot and its impact on oncology care: Memorial Sloan Kettering Cancer Center2016 Available from: http://drugpricinglab.org/wp-content/uploads/2016/04/Part-B-Payment-Phase-1-Report-042216.pdfAccessed April 11, 2016
   Google Scholar
• Health Resources & Services Administration340B Drug Pricing ProgramWashington, DCUS Department of Health & Human Services2017 [updated March 20, 2017]. Available from: https://www.hrsa.gov/opa/Accessed April 6, 2017
   Google Scholar
• PyensonBSFitchKVPelizzariPMCost drivers of cancer care: a retrospective analysis of Medicare and commercially insured population claim data, 2004–2014New York, NYMilliman2016 Available from: http://www.milliman.com/insight/2016/Cost-drivers-of-cancer-care-A-retrospective-analysis-of-Medicare-and-commercially-insured-population-claim-data-2004-2014/Accessed April 6, 2017
   Google Scholar
• DicksonVCMS finalizes site-neutral payment ruleNew York, NYModern Healthcare2016 [updated November 1, 2106]. Available from: http://www.modernhealthcare.com/article/20161101/NEWS/161109982Accessed April 6, 2017
   Google Scholar
• Avalere HealthPatient out-of-pocket costs for biosimilars in Medicare Part DWashington, DCAvalere Health2016 Available from: http://go.avalere.com/acton/attachment/12909/f-02c0/1/-/-/-/-/20160412_Patient%20OOP%20for%20Biosimilars%20in%20Part%20D.pdfAccessed April 6, 2017
   Google Scholar
• KellyCBiosimilars pricing in Medicare Part D needs legislative fix, Avalere saysNew York, NYPink Sheet Daily2016 Available from: https://pink.pharmamedtechbi.com/PS079306/Biosimilars-Pricing-In-Medicare-Part-D-Needs-Legislative-Fix-Avalere-SaysAccessed April 6, 2017
   Google Scholar
• KopenskiFRHolcombKUnderstanding biosimilars and projecting the cost savings to employers: updateSeattle, WAMilliman2015 Available from: http://www.milliman.com/insight/2015/Understanding-biosimilars-and-projecting-the-cost-savings-to-employers-Update/Accessed April 6, 2017
   Google Scholar
• BanthiaVBiosimilar regulation: bringing the United States up to speed with other marketsMinn J Law Sci Technol2015162879916
   Google Scholar
• FelixAEGuptaACohenJPRiggsKBarriers to market uptake of biosimilars in the USGaBi J201633108115
   Google Scholar
• DunneSSDunneCPWhat do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugsBMC Med20152913173
   Web of Science ®Google Scholar
• BabarZUDScahillSInterventions promoting the acceptance and uptake of generic medicines: a narrative review of the literatureHealth Policy2014117328529624973926
   PubMed Web of Science ®Google Scholar
• IMS Institute for Healthcare InformaticsThe role of generic medicines in sustaining healthcare systems: a European perspectiveParsippany, NJIMS Health2015 Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/IIHI_Generics_Health-care_Brief.pdfAccessed April 7, 2017
   Google Scholar
• Centers for Medicare & Medicaid ServicesOncology care modelBaltimore, MDUS Department of Health & Human Services2016 [updated January 6, 2017]. Available from: https://innovation.cms.gov/initiatives/oncology-care/Accessed April 6, 2017
   Google Scholar
• GoldJAccountable Care Organizations, explainedMenlo Park, CAKaiser Health News2015 [updated September 14, 2015]. Available from: http://khn.org/news/aco-accountable-care-organization-faq/Accessed April 6, 2017
   Google Scholar
• PatelBNAudetPRA review of approaches for the management of specialty pharmaceuticals in the United StatesPharmacoeconomics201432111105111425118989
   PubMed Web of Science ®Google Scholar